Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS016 in Mild/Moderate or Asymptomatic COVID-19
NCT04780321Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of etesevimab in coronavirus disease 2019 (COVID-19), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Oct 2020; status: completed.
02
Drugs
etesevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04780321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780321.